Seminars in Oncology
Volume 33 , Pages 8-17 , December 2006

Maximizing the Delivery of Intraperitoneal Therapy While Minimizing Drug Toxicity and Maintaining Quality of Life

  • David S. Alberts

      Affiliations

    • Dr Alberts has received grant and research support from and serves on the speakers bureau for MedImmune, Inc. He is also a paid consultant for Amgen Inc.
    • Corresponding Author InformationAddress reprint requests to David S. Alberts, MD, Arizona Cancer Center, 1515 N. Campbell Ave, Tucson, AZ 85274.
    • ,
  • Ardie Delforge

References 

  1. NCI Clinical Announcement on Intraperitoneal Therapy for Ovarian Cancer. Available at: http://www.cancer.gov/clinicaltrials/developments/IPchemo-digest (accessed January 5, 2006)
  2. Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 1996;335:1950–1955
  3. Armstrong DK, Bundy B, Wenzel L, et al. Phase III randomized trial of intravenous cisplatin and paclitaxel versus an intensive regimen of intravenous paclitaxel, intraperitoneal cisplatin and intraperitoneal paclitaxel in stage III ovarian cancer: A Gynecologic Oncology Group Study. N Engl J Med. 2006;354:34–43
  4. Markman M, Bundy BN, Alberts DS, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group and Eastern Cooperative Oncology Group. J Clin Oncol. 2001;19:1001–1007
  5. Alberts DS, Markman M, Armstrong D, et al. Intraperitoneal therapy for stage III ovarian cancer: A therapy whose time has come!. J Clin Oncol. 2002;20:3944–3946
  6. Fujiwara K, Markman M, Morgan M, et al. Intraperitoneal carboplatin-based chemotherapy for epithelial ovarian cancer. Gynecol Oncol. 2005;97:10–15
  7. Walker JL, Armstrong DK, Huang HQ, et al. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecol Oncol. 2006;100:27–32
  8. Wenzel L, Huang H, Armstrong D, et al. Quality of life (QOL) results of a randomized study of intravenous (IV) paclitaxel and cisplatin vs (IV paclitaxel, intraperitoneal (IP) cisplatin and IP paclitaxel in optimal stage III epithelial ovarian cancer (OC): A Gynecologic Oncology Group trial). Proc Am Soc Clin Oncol. 2004;23:454;(abstr 5026)
  9. Alberts DS. A unifying vision of cancer therapy for the 21st century. J Clin Oncol. 1999;17:13–21
  10. Ozols RF, Locker GY, Doroshow JH, et al. Pharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer. Cancer Res. 1979;39:3209–3214
  11. Markman M, Walker JL. Intraperitoneal chemotherapy of ovarian cancer: A review, with a focus on practical aspects of treatment. J Clin Oncol. 2006;24:988–993
  12. Makhija S, Leitao M, Sabbatini P, et al. Complications associated with intraperitoneal chemotherapy catheters. Gynecol Oncol. 2001;81:77–81
  13. Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol. 2003;21:3194–3200
  14. NCCN Antiemesis Guidelines version 2.2006. Available at: http://www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdf (accessed September 11, 2006)
  15. Casper ES, Kelsen DP, Alcock NW, et al. IP cisplatin in patients with malignant ascites: Pharmacokinetic evaluation and comparison with the iv route. Cancer Treat Rep. 1983;67:235–238
  16. Howell SB, Pfeifle CE, Wung WE, et al. Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med. 1982;97:845–851
  17. Lopez JA, Krikorian JG, Reich SD, et al. Clinical pharmacology of intraperitoneal cisplatin. Gynecol Oncol. 1985;20:1–9
  18. Francis P, Rowinsky E, Schneider J, et al. Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: A Gynecologic Oncology Group Pilot Study. J Clin Oncol. 1995;13:2961–2967
  19. Markman M, Reichman B, Hakes T, et al. Impact on survival of surgically defined favorable responses to salvage intraperitoneal chemotherapy in small-volume residual ovarian cancer. J Clin Oncol. 1992;10:1479–1484
  20. Schneider JG. Intraperitoneal chemotherapy. Obstet Gynecol Clin North Am. 1994;21:195–212
  21. Kemp G, Rose Pl, Lurain J, et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: Results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol. 1996;14:2101–2112
  22. Hilpert F, Stahle A, Tome O, et al. Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy – A double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gynakologische Onkologoie (AGO) Ovarian Cancer Study Group. Support Care Cancer. 2005;13:797–805
  23. Kanat O, Evrensel T, Baran I, et al. Protective effect of amifostine against toxicity of paclitaxel and carboplatin in non-small cell lung cancer: A single center randomized study. Med Oncol. 2003;20:237–245
  24. Lorusso D, Ferrandina G, Greggi S, et al. Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients. Ann Oncol. 2003;14:1086–1093
  25. De Vos FY, Bos AM, Schaapveld M, et al. A randomized phase II study of paclitaxel with carboplatin +/− amifostine as first line treatment in advanced ovarian carcinoma. Gynecol Oncol. 2005;97:60–67
  26. Leong SS, Tan EH, Fong KW, et al. Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non–small-cell lung cancer. J Clin Oncol. 2003;21:1767–1774
  27. Ethyol package insert. Gaithersburg, MD, MedImmune Oncology. Available at: http://www.medimmune.com/pdf/products/ethyol_pi.pdf (accessed September 13, 2006)
  28. Schuchter LM, Hensley ML, Meropol NJ, et al. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: Clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2002;20:2895–2903
  29. Blumberg AL, Nelson DF, Gramkowski M, et al. Clinical trials of WR-2721 with radiation therapy. Int J Radiat Oncol Biol Phys. 1982;8:561–563
  30. Kligerman MM, Glover DJ, Turrisi A, et al. Toxicity of WR-2721 administered in single and multiple doses. Int J Radiat Oncol Biol Phys. 1984;10:1773–1776
  31. Shaw LM, Turrisi AT, Glover DJ, et al. Human pharmacokinetics of WR-2721. Int J Radiat Oncol Biol Phys. 1986;12:1501–1504
  32. Boccia R. Improved tolerability of amifostine with rapid infusion and optimal patient preparation. Semin Oncol. 2002;29(suppl 19):9–13
  33. Boccia RV, Alster M, Houskamp E. Amifostine (Ethyol) given by rapid IV push is safe and tolerable. Proc Am Soc Clin Oncol. 2001;20:300b;(abstr 2953)
  34. Kemp GM, Kemp CB, Mallee LM, et al. Improved patient tolerability with short infusion amifostine (Ethyol). Proc Am Soc Clin Oncol. 2002;21:267b;(abstr 2888)
  35. Koukourakis MI. Amifostine in clinical oncology: Current use and future applications. Anticancer Drugs. 2002;13:181–209
  36. Hensley ML, Schuchter LM, Lindley C, et al. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol. 1999;17:3333–3355
  37. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med. 1991;325:164–170
  38. Heil G, Hoelzer D, Sanz MA, et al. The International Acute Myeloid Leukemia Study Group A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. Blood. 1997;90:4710–4718
  39. Trillet-Lenoir V, Green J, Manegold C, et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer. 1993;29a:319–324
  40. Biganzoli L, Untch M, Skacel T, et al. Neulasta (pegfilgrastim): A once-per-cycle option for the management of chemotherapy-induced neutropenia. Semin Oncol. 2004;31(suppl 8):27–34
  41. Neuopogen (filgrastim) prescribing information. Thousand Oaks, CA, Amgen Inc. Available at: http://www.amgen.com/pdfs/misc/neupogen_pi.pdf (accessed September 14, 2006)
  42. Morstyn G, Dexter T, Foote M. Filgrastim (r-metHuG-CSF) in Clinical Practice. Ed 2.. New York, NY: Marcel Dekker; 1998;
  43. Valerius T, Elsasser D, Repp R, et al. HLA Class-II antibodies recruit G-CSF activated neutrophils for treatment of B-cell malignancies. Leuk Lymphoma. 1997;26:261–269
  44. Johnston E, Crawford J, Blackwell S, et al. Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol. 2000;18:2522–2528
  45. Holmes FA, Jones SE, O’Shaughnessy J, et al. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: A multicenter dose-finding study in women with breast cancer. Ann Oncol. 2002;13:903–909
  46. McKenna P, Korach E, Andersen P. Filgrastim-SD, a sustained duration form of filgrastim (rhuG-CSF) has similar effects on neutrophil function compared to filgrastim. Blood. 1998;92(suppl 1):379a;(abstr 1562)
  47. Neulasta Product Information. Thousand Oaks, CA, Amgen Inc. Available at: http://www.neulasta.com/patient/pi.jsp#injection_site_selection_and_preparation (accessed October 20, 2006)
  48. Gynecologic Oncology Group IP Chemotherapy Educational Materials. Available at: http://www.gog.org/ipchemoed/ipchemoed.html (accessed August 28, 2006)
  49. American Society of Clinical Oncology. Available at: http://www.asco.org (accessed August 28, 2006)
  50. Oncology Nursing Society. Available at: http://www.ons.org (accessed August 28, 2006)
  51. Thompson SD, Horne AL. Intraperitoneal Chemotherapy for Ovarian Cancer: A Nursing Management Perspective. 2006;Available at: http://www.ovariancancercenter.org (accessed August 28)

 This activity is supported by an unrestricted educational grant from MedImmune Oncology, Inc., a subsidiary of MedImmune, Inc.

PII: S0093-7754(06)00425-8

doi: 10.1053/j.seminoncol.2006.11.003

Seminars in Oncology
Volume 33 , Pages 8-17 , December 2006

Article Tools